Core Points - Cannara Biotech Inc. will release its financial results for the fiscal fourth quarter and fiscal year ended August 31, 2025, on November 24, 2025, at 7:00 a.m. ET [1] - The earnings webcast will be hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak on the same day at 11:00 a.m. ET, featuring prepared remarks and a Q&A session [2] - Investors are encouraged to submit questions in advance via email, with priority given to those submitted before the session [3] Board Update - The company announced the passing of Jack M. Kay, a long-serving member of the Board of Directors, who contributed over five decades of leadership experience in the pharmaceutical sector [4][5] - Mr. Kay held several senior executive positions at Apotex Inc. and served in key leadership roles across various pharmaceutical and biotechnology organizations [5] - The company extends its condolences to Mr. Kay's family and expresses gratitude for his contributions [6] Company Overview - Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products, operating two mega facilities in Québec that span over 1,650,000 sq. ft. [8] - The company has a potential annualized cultivation output of 100,000 kg, leveraging low electricity costs in Québec to produce affordable premium-grade cannabis [8]

Company Leadership Transition - Assertio Holdings, Inc. has appointed Mark L. Reisenauer as the new CEO, effective immediately, succeeding Brendan P. O'Grady [1][2] - The Board of Directors believes Reisenauer is well-suited to lead the company into its next growth phase, focusing on enhancing efficiency and delivering long-term value [2] Upcoming Financial Results - Assertio will release its third quarter 2025 financial results on November 10, 2025, after market close [3] - A live webcast conference call will be held at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide updates on the company's strategic plans for 2025 [3] Mark Reisenauer's Background - Mark Reisenauer has over 30 years of experience in the oncology space, previously serving as President of U.S. Commercial at Astellas Pharmaceuticals, where he grew sales to nearly $5 billion [5] - He has a strong track record in building and launching franchises and products, making him highly qualified for the CEO role at Assertio [2][5] Company Overview - Assertio is a pharmaceutical company focused on marketing differentiated products in oncology, neurology, and pain management [6][7]

Company Overview - Resideo Technologies, Inc. is a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential and commercial end-markets [4] - The company specializes in home heating, ventilation, and air conditioning controls, smoke and carbon monoxide detection, home safety and fire suppression products, and security markets [4] - Resideo's solutions and services are utilized in over 150 million residential and commercial spaces globally, with tens of millions of new devices sold annually [4] Upcoming Financial Results - Resideo will release its second quarter 2025 financial results after the close of the New York Stock Exchange on August 5, 2025 [1] - A conference call and simultaneous webcast to discuss the results will take place on the same day at 5:00 p.m. ET [1] Accessing Information - Interested investors can listen to the webcast of the conference call via the Investor Relations section of Resideo's website, where related materials will be posted prior to the call [2] - A replay of the webcast will be available following the presentation [2] - The conference call can also be accessed by dialing 888-660-6357 (U.S., toll-free) or 1-929-201-6127 (international) using the conference title "Resideo Second Quarter 2025 Earnings Call" or the conference ID: 7301399 [3]